Myriad Genetics Earns US Patent for 47 BRCA1 Gene Mutations | GenomeWeb

SALT LAKE CITY--Myriad Genetics here has received a patent for 47 different BRCA1 gene mutations that increase the risk of breast and ovarian cancer. The company also received a notice of allowance from the US Patent and Trademark Office for four additional BRCA1 patent applications, including use of the gene or its protein as a breast cancer diagnostic.

Myriad said it will now use its proprietary functional genomic tools, including its ProNet database, to try to uncover the gene's biological role in the disease process.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.